Nitazoxanide was recommended for further in vivo study after demonstrating low concentration inhibition of SARS-CoV-2. Studies have demonstrated that the initial spike protein priming with serine transmembrane protease 2 (TMPRSS2) is essential for the entry of SARS-CoV-2 via interaction with the ACE 2 receptor.
Nitazaxonide imependekezwa kwa utafiti zaidi wa vivo baada ya kuonyesha uzuizi wa kiwango cha chini cha ukolezo wa SARS-CoV-2. Utafiti umeonyesha kwamba ongezeko la maandalizi ya protini kwa kutumia transmembrane protease serine 2 (TMPRSS2) ni muhimu kwa uingiaji wa SARS-CpV-2 kupitia mtagusano na vipokezi vya ACE2.